Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

REJUVIMMUNE Partial reprogramming for hematopoietic system rejuvenation: Impact on systemic hallmarks of aging and health span

Coordinator
Karolinska Institutet, Sweden
Runs
1 September 2026 to 31 August 2028
Status
Running
EU funding
€252k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101204756

What the project is doing

In the project's own words, from its summary on CORDIS.

Aging is a complex process, encompassing the decline numerous cell types and organs. In this regard, recent progress suggests that the hematopoietic system is particularly influential; as we age, hematopoietic stem cells (HSCs) preferentially differentiate toward the myeloid lineage, thus losing their ability to regenerate fully functional blood tissue. Furthermore, a decline in the effector capacity of immune cells accounts for insufficient immunosurveillance of senescent cells, leading to their accumulation throughout the body.

From a therapeutic perspective, the hematopoietic system is particularly malleable to rejuvenating interventions. In recent years, strategies of epigenetic reprogramming achieved through the transient expression of the Yamanaka factors Oct4-Sox2-Klf4 (OSK) and the facultative expression of c-Myc -referred to as partial reprogramming- has progressively garnered attention for its potential application in regenerative medicine.

Their capacity to transiently push fate-committed cells back to their developmental program and to remove epigenetic marks of damage enhances the capacity of tissues to regenerate after injury in several preclinical models. However, it is poorly understood whether single-organ partial reprogramming affects other tissues and health span, without risks for secondary transformation, undermining the translational potential for humans.

Across the REJUVIMMUNE project, I leverage on these limitations to develop unique tools –mRNA therapeutics and partial reprogramming mimicking cocktails (PRMCs)– for targeting partial reprogramming on HSCs (Objective 1) and elucidate cell intrinsic and extrinsic effects of OSK-rejuvenation on blood cells -including immune cells- and systemic aging, respectively (Objective 2). In summary, the strategies proposed in this action hold great potential to counteract hematopoietic senescence and mitigating age-associated decline in organismal function, enhancing health span and organismal resilience.

Topics

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI